← Eichor
Study identifier: NCT07432347 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches

Condition: Hepatocarcinoma  ·  Sponsor: Niguarda Hospital

PhaseN/A
Planned participants270
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a national, observational, retrospective, cross-sectional, non-profit study focused on patients with HCC. The study aims to characterize the expression and function of novel noncoding regulatory transcripts, including those containing TEsin the microenvironment of liver tumors, with emphasis on their role in T cell dysfunction.

This description comes directly from the study's public registry record.

Talk to the study team

Gianluca Mauri, MD  ·  +39026444  ·  gianluca.mauri@ospedaleniguarda.it

Always discuss trial participation with your own doctor first.

Locations (1)

ASST GOM NiguardaMilan, Lombardy, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07432347